Pfizer lines up an $830M alliance with Arvinas on protein degradation

Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.

• Source: Endpts
• 489
• January 10, 2018